A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved drug, Forteo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Postmenopausal women with osteoporosis

Exclusion Criteria:

• Any therapies or products affecting bone turnover within 12 months of Screening.

• Bisphosphonate treatment >1 month in total duration at any time in the past.

• In addition, patients must be bisphosphonate-treatment-free for at least 12 months prior to Screening.